Collectively, these data will provide novel insights into features and outcomes of MAS in patients treated with IL‐1–targeting therapies and further assess the relevance of the EULAR/ACR/PRINTO MAS 2016 criteria in this population. This evidence concerns the gene IL1B and macrophage activation syndrome.